- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02857062
To Evaluate the in Use Tolerance of E45 Eczema Repair Emollient in Babies and Children With (Very(Dry/Atopic Skin
An Open Label, In-use Tolerance Study in Babies and Children With Dry/Atopic and Very Dry/Atopic Skin, to Evaluate the Acceptability and Skin Tolerability of E45 Eczema Repair Emollient for the Treatment of Atopic or Eczema Prone Skin
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigation is an open label, in-use cutaneous tolerance investigation in children and babies with dry/atopic and very dry/atopic skin, to evaluate the acceptability and skin tolerability of E45 Eczema Repair Emollient.
The investigation will be an 'at home' user investigation where the test product will be applied by the parent/legal guardian to a pre-defined test site (arm or leg) between 2 to 3 times daily, consecutively for 14 days.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- be female or male
- be a child aged from ≥3 years to < 12 years or a baby aged from ≥3 months to < 36 months at screening
- be phototype I - IV (Fitzpatrick Phototyping Scale)
- have skin that is dry/atopic or very dry/atopic (confirmed by the Dermatologist in consultation with the parent/legal guardian)
- have mild atopic eczema (as confirmed by the Dermatologist in consultation with the parent/legal guardian) but not undergoing steroid treatment for the condition
- have only few or no pigmentation on the selected test site
be in general good health and mental condition
In addition the parent/legal guardian must:
- Both parents in case of shared custody/legal guardian will provide written informed consent for their child/baby to participate in the investigation (children aged 6 years and above, capable of understanding the investigation after it has been explained to them, will be asked to provide assent. Pre-schoolers (2-5 years) will be allowed to express a level of assent verbally relating to their ability to do so)
- agree to attend the investigation centre, with the child/baby, on the predefined days
- be willing and capable to follow the investigation requirements
Exclusion Criteria:
- have chronic or acute skin diseases, except atopic eczema on any part of the body
- have an active flare up of atopic eczema on any sites of the body at screening
- known allergy or sensitivity to cosmetic products and/or any ingredients of the investigational product.
- any systemic illness that would impact on the subjects safety or wellbeing and/or affect the response of the skin or the interpretation of the test results at screening (Day -14 to -7)
receiving the following topical or systemic treatments at baseline (Day 0);
- anti-inflammatory and/or anti-histamines during the previous week
- cough suppressants and/or topical or inhaled corticosteroids during the previous 2 weeks
- retinoids and/or immunosuppressants during the previous 6 months
- have diabetes, acute cardiac and circulatory diseases, HIV, hepatitis
- participation in other studies/investigations on any part of the body during the last 4 weeks
- use of dermatological therapeutics on the body within 7 days prior to baseline (Day 0) (use of such products on the face, trunk, hands and nappy area is permitted)
- swimming within 48 hours prior to baseline (Day 0)
- intensive/prolonged exposure to the sun within 30 days prior to screening
- planned changes to subject's diet during the investigation (e.g. weaning)
- subjects whose parent/legal guardian are employees or who work for a manufacturer of personal care products or for the testing facility
- subjects in protective care
- subjects whose parent/legal guardian (who will be applying the investigation product) is allergic to the investigation device ingredients
- Any clinically significant and relevant abnormalities of medical history and/or any condition or medication that would impact on the subject safety or well-being and/or affect the response of the skin or the interpretation of the test results in the opinion of the Principal Investigator or designee
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: E45 Eczema Repair Emollient
Open label, single arm study to evaluate the skin tolerance of E45 Eczema Repair Emollient in babies and children
|
E45 Eczema Repair Emollient
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cutaneous Tolerance
Time Frame: 14 Days
|
The total irritancy score (Erythema score + Oedema score + Papules score + Vesicles score) for each subject from baseline to end of study as observed by the investigation Dermatologist.
|
14 Days
|
Parental Assessment of Cutaneous Tolerance
Time Frame: 14 Days
|
The dermatologist will ask the parent/legal guardian to provide their assessment of tolerance by asking the parent/legal guardian if they considered the product to be well tolerated by their child/baby's skin
|
14 Days
|
Global Assessment of Cutaneous Tolerance
Time Frame: 14 Days
|
The dermatologist will make a 'global assessment' of tolerance for each subject based on reported product use/compliance
|
14 Days
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09224-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis / Eczema
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
University of California, DavisCompletedAtopic Dermatitis | Hand Eczema | Atopic Eczema | Infantile EczemaUnited States
-
Kari NadeauKing's College London; National Institute of Allergy and Infectious Diseases... and other collaboratorsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Eczema, InfantileUnited States, United Kingdom
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Petra LarmoCliniscan LtdTerminated
-
Groningen Research Institute for Asthma and COPDNumico Research Wageningen, the NetherlandsCompletedAtopic Dermatitis | Atopic Eczema | Infantile EczemaNetherlands
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
University College CorkCompletedEczema | Food Allergy | Eczema, Infantile | Eczema Atopic DermatitisIreland
-
ShaperonNot yet recruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of Scalp
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
Clinical Trials on E45 Eczema Repair Emollient
-
Reckitt Benckiser Healthcare (UK) LimitedSkin Investigation TechnologyCompleted
-
Oregon Health and Science UniversityCompleted